Inovio Pharmaceuticals, Inc. News (NASDAQ:INO)

DateTimeSource
Headline
03/21/20178:00AMGLOBEGeorge Bickerstaff Elected to Inovio’s Board of Directors
PLYMOUTH MEETING, Pa., March 21, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today the election of George Bickerstaff to its Board of Directors.  Mr. Bickerstaff is an internationally recognized expert in finance, healthcare and information technology.  He has served Novartis... More...>>
03/15/20174:05PMGLOBEInovio Pharmaceuticals Reports 2016 Fourth Quarter and Year End Financial Results
PLYMOUTH MEETING, Pa., March 15, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today reported financial results for the fourth quarter and year ended December 31, 2016. Total revenue was $8.5 million and $35.4 million for the quarter and year ended December 31, 2016, as compared to $5.9 million and... More...>>
03/09/20178:00AMGLOBEInovio Pharmaceuticals to Report Fourth Quarter and Year End 2016 Financial Results on March 15, 2017
PLYMOUTH MEETING, Pa., March 09, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it will host a conference call and live webcast to discuss its 2016 fourth quarter and year end financial results and provide a corporate update on Wednesday, March 15, 2017 at 4:30 p.m. ET. A live and... More...>>
02/27/20177:00AMGLOBEInovio’s SynCon® WT1 Cancer Antigen Breaks Tolerance, Highlights Potential for Universal Cancer Immunotherapy
PLYMOUTH MEETING, Pa., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that its SynCon® WT1 cancer immunotherapy was capable of breaking immune tolerance and inducing neo-antigen-like T cell responses to cause tumor regression in pre-clinical studies. Breaking tolerance has... More...>>
02/23/20177:00AMGLOBEInovio Reports New Positive Clinical Data on Vaccine Advances in the Fight Against Emerging Infectious Diseases
Significant immune responses observed in 100% of Zika-vaccinated subjects and 98% of MERS-vaccinated human subjects in separate phase I studies  Data reported at Coalition for Epidemic Preparedness Innovation (CEPI) meeting PLYMOUTH MEETING, Pa., Feb. 23, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO... More...>>
02/13/20176:00AMGLOBEInovio and ApolloBio to Collaborate on Development and Commercialization of HPV Pre-cancer Immunotherapy VGX-3100 in Greater ...
PLYMOUTH MEETING, Pa., Feb. 13, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that it has entered into a collaboration and license agreement providing ApolloBio Corporation (NEEQ:430187) with the exclusive right to develop and commercialize VGX-3100, Inovio’s DNA immunotherapy product... More...>>
01/30/20178:00AMGLOBEInovio Pharmaceuticals to Participate in Upcoming Investment Conferences
PLYMOUTH MEETING, Pa., Jan. 30, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the Company will participate in the following upcoming investment conferences: BIO CEO & Investor ConferenceFireside chatDr. J. Joseph Kim, President & CEO10:00AM ET, February 13, 2017The Waldorf... More...>>
12/21/20168:00AMGLOBEInovio’s Zika Vaccine Generates Robust Immune Responses in First Human Study
PLYMOUTH MEETING, Pa., Dec. 21, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced its DNA-based Zika vaccine (GLS-5700) generated robust antigen-specific antibody responses in a first-in-man, multi-center phase I trial. In initial testing, Zika-naïve subjects in both low dose and high... More...>>
12/06/20168:00AMGLOBEInovio MERS Vaccine Development to be Expanded with Funding from International Vaccine Institute
PLYMOUTH MEETING, Pa., Dec. 06, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the International Vaccine Institute (IVI) will provide new funding and support to further advance GLS-5300, Inovio’s vaccine to prevent Middle East Respiratory Syndrome (MERS) virus infection. Inovio... More...>>
12/01/20169:00AMGLOBEInovio Pharmaceuticals Awarded $6.1 Million Sub-grant Through Wistar Institute to Develop DNA-based Monoclonal Antibodies Aga...
Grant Provides Funding to Help Prepare New Zika Therapy for Human Trials Inovio Already in Two Human Trials for its Preventive Zika Vaccine PLYMOUTH MEETING, Pa. & PHILADELPHIA, Dec. 01, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it has been awarded a $6.1 million sub-grant... More...>>
11/25/20168:00AMGLOBEInovio Applies to Cease Reporting to Canadian Securities Regulatory Authorities; NASDAQ Listing and US Reporting Unaffected
PLYMOUTH MEETING, Pa., Nov. 25, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that further to the voluntary delisting of Genetronics Biomedical Corporation, a predecessor of the Company, from the Toronto Stock Exchange on January 17, 2003, it has applied to the British Columbia Securities... More...>>
11/21/20168:00AMGLOBEInovio’s Co-Founder and Chair of its Scientific Advisory Board Selected as a Top 20 Translational Researcher
PLYMOUTH MEETING, Pa., Nov. 21, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that Dr. David B. Weiner, its co-founder, board member and chair of its scientific advisory board, has been selected as a “Top 20 Translational Researcher” for the year 2015 by the editors of Nature Biotechnology... More...>>
11/16/20168:00AMGLOBEInovio Wins Deloitte’s “Fast 500” Growth Award
PLYMOUTH MEETING, Pa., Nov. 16, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO), today announced it ranked No. 107 on Deloitte’s Technology Fast 500™, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in North America. Technology Fast... More...>>
11/14/20167:00AMGLOBEInovio’s Cancer Immunotherapy (INO-3112) Generates T Cell Immune Responses in Tumor Tissue and Peripheral Blood in Patients...
PLYMOUTH MEETING, Pa., Nov. 14, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO), today announced an interim data analysis showing that its INO-3112 cancer immunotherapy product generated antigen-specific CD8+ killer T cell responses measured both in tumor tissue and in peripheral blood from subjects... More...>>
11/10/201610:00AMGLOBEInovio Pharmaceuticals Zika Vaccine Protects Animals from Infection, Brain Damage and Death
Article published in npj Vaccines demonstrates that DNA vaccine protected 100% of animals from Zika infection after exposure to the virus PLYMOUTH MEETING, Pa., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that Inovio and its collaborators have published results in Nature... More...>>
11/09/20167:30AMGLOBEInovio Pharmaceuticals Reports 2016 Third Quarter Financial Results
PLYMOUTH MEETING, Pa., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today reported financial results for the quarter ended September 30, 2016. The following financial results provide a year-over-year comparison of the third quarter in 2016 and 2015. Total revenue was $12.5 million compared... More...>>
11/04/20168:00AMGLOBEInovio Pharmaceuticals to Participate in Upcoming Investment Conferences
PLYMOUTH MEETING, Pa., Nov. 04, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the Company will participate at the following upcoming investment conferences: Global Mizuho Investor Conference (MIC)One-on-one meetings onlyDr. Niranjan Sardesai, COONovember 14, 2016Omni Berkshire... More...>>
10/26/20168:00AMGLOBEInovio Pharmaceuticals to Report Third Quarter 2016 Financial Results November 9, 2016
PLYMOUTH MEETING, Pa., Oct. 26, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it will host a conference call and live webcast to discuss its 2016 third quarter financial results and provide a corporate update on Wednesday, November 9, 2016 at 8:30 a.m. ET. A live and archived version... More...>>
10/24/20168:00AMGLOBEInovio Announces FDA Request for Additional Information For Phase III Program; Trial Initiation Delayed
PLYMOUTH MEETING, Pa., Oct. 24, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on its proposed phase III clinical program for VGX-3100. A clinical hold is a notification issued by the FDA to a trial sponsor to... More...>>
10/21/20168:00AMGLOBEInovio CEO Selected As 2016 Healthcare Innovator
PLYMOUTH MEETING, Pa., Oct. 21, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO), today announced that its President and Chief Executive Officer, Dr. J. Joseph Kim, has been selected as a 2016 Healthcare Innovator by a panel of scientific and medical experts convened by the Philadelphia Business Journal... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V:us D:20170330 00:46:19